- Home
- MIRM vs NML Comparison
MIRM vs NML Comparison
Compare MIRM & NML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- NML
- Stock Information
- Founded
- MIRM 2018
- NML 2012
- Country
- MIRM United States
- NML United States
- Employees
- MIRM N/A
- NML N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- NML Finance/Investors Services
- Sector
- MIRM Health Care
- NML Finance
- Exchange
- MIRM Nasdaq
- NML Nasdaq
- Market Cap
- MIRM 1.9B
- NML 454.4M
- IPO Year
- MIRM 2019
- NML N/A
- Fundamental
- Price
- MIRM $39.10
- NML $8.36
- Analyst Decision
- MIRM Strong Buy
- NML
- Analyst Count
- MIRM 11
- NML 0
- Target Price
- MIRM $58.55
- NML N/A
- AVG Volume (30 Days)
- MIRM 476.2K
- NML 219.3K
- Earning Date
- MIRM 05-07-2025
- NML 01-01-0001
- Dividend Yield
- MIRM N/A
- NML 9.75%
- EPS Growth
- MIRM N/A
- NML N/A
- EPS
- MIRM N/A
- NML N/A
- Revenue
- MIRM $336,888,000.00
- NML N/A
- Revenue This Year
- MIRM $29.51
- NML N/A
- Revenue Next Year
- MIRM $20.27
- NML N/A
- P/E Ratio
- MIRM N/A
- NML N/A
- Revenue Growth
- MIRM 80.76
- NML N/A
- 52 Week Low
- MIRM $23.14
- NML $6.09
- 52 Week High
- MIRM $54.23
- NML $7.33
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- NML 46.19
- Support Level
- MIRM $37.83
- NML $7.70
- Resistance Level
- MIRM $40.32
- NML $8.42
- Average True Range (ATR)
- MIRM 2.47
- NML 0.41
- MACD
- MIRM -0.33
- NML -0.02
- Stochastic Oscillator
- MIRM 25.14
- NML 58.88
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.